GAMMA Investing’s Verrica Pharmaceuticals VRCA Stock Holding History

GAMMA Investing’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4	Closed	-$277	–	3652
2024 Q2	$277	Buy	+4	New	+$307	﹤0.01%	3283

Other funds holding VRCA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GAMMA Investing's VRCA Position: Q3 2024 in Review

GAMMA Investing sold out of Verrica Pharmaceuticals (VRCA) in Q3 2024, closing a stake of 4 shares — an estimated $277 sold.

GAMMA Investing first reported a position in VRCA in Q2 2024 and held it in 1 quarter. The position peaked at $277 in Q2 2024. 79 funds tracked by Wall St. Rank hold VRCA as of Q3 2024.

GAMMA Investing reported no remaining Verrica Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
GAMMA Investing sold 4 Verrica Pharmaceuticals shares in Q3 2024, an estimated $277.
GAMMA Investing first reported a position in Verrica Pharmaceuticals in Q2 2024 and held it in 1 quarter.
GAMMA Investing's Verrica Pharmaceuticals position peaked at $277 in Q2 2024.
79 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2024.

Based on GAMMA Investing's 13F filing for Q3 2024, filed 7 Oct 2024.